Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (461-470 of 527) with videos related to

Pageof 53
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
The Journal of Infectious Diseases|September 25, 2019
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral TherapyHwai-I Yang, Ming-Lun Yeh, Grace L Wong, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosisJie Li, Liang Xu, Fajuan Rui, et al.
Cancer Cell|December 14, 2016
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway InhibitionShigeki Nakagawa, Lan Wei, Won Min Song, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2023
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal StudyAngela Chau, Ming-Lun Yeh, Pei-Chien Tsai, et al.
Gut|March 20, 2021
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVictor Sapena, Marco Enea, Ferran Torres, et al.
Pageof 53

Showing results (461-470 of 527) with videos related to

Sort By:
Pageof 53
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Hepatology Communications|October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensusJee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
The Journal of Infectious Diseases|September 25, 2019
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral TherapyHwai-I Yang, Ming-Lun Yeh, Grace L Wong, et al.
The American Journal of Gastroenterology|December 12, 2025
Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B studyJie Li, Joanne Kimiko Liu, Angela Chau, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosisJie Li, Liang Xu, Fajuan Rui, et al.
Cancer Cell|December 14, 2016
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway InhibitionShigeki Nakagawa, Lan Wei, Won Min Song, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2023
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal StudyAngela Chau, Ming-Lun Yeh, Pei-Chien Tsai, et al.
Gut|March 20, 2021
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVictor Sapena, Marco Enea, Ferran Torres, et al.
Pageof 53